medigraphic.com
ISSN 0016-3813 (Print)

2001, Number 5

<< Back Next >>

Gac Med Mex 2001; 137 (5)

Toxina botulínica como tratamiento de la espasticidad y distonía en la parálisis cerebral infantil.

Aguilar-Rebolledo F, Hernández-Sánchez J, Darío Rayo-Mares, Soriano FF, García-Muñoz L, Ruiz-Ponce J, Garrido-Ramírez E

Language: Spanish
References: 36
Page: 403-411
PDF size: 57.83 Kb.


ABSTRACT

Treatment of spasticity and dystonía in PCI with Botulinum toxin A. Background: Botulinum-A (NxTxBoA) toxin produce neuromuscular blockade, it has been effective with therapeutic purposes in strabismus, focal dystonias and spasticity. Objective: Evaluate the therapeutically effects off NxTxBoA in cerebral palsy (CP) spastic and/or dystonic in children. Prospective study. Material and Methods: 12 CP patients (8 spastic and 4 spastic/dystonic) were treated with NxTxBoA in affected muscles at least for 2 doses by up 12 months. The indication was: improve limb function, to avoid surgical correction or improve hygienic or dressing. Ashworth Spasticity Scale (ASS), functional scale for Dystonic Sindou-Millet (SMS) and O´Brien Global Assessment Scale (OGAS) were used to evaluate improvement. Statistical Methods: No parametric tests, Wilcoxon´s rang’s test and sign test were used with p‹0.05. Results: Total doses session was 3-10 U/kg. AAS showed muscle spasticity improvement in two grades in 8 patients, and one grade in the rest (p= 0.004). SMS showed the muscle dystonic improve up 60% in two patients improve 50% in others (p=0.006). OGAS demonstrated a good correlation. Mean treatment effect during 4.8 months (rank 4 to 10 m). Two patients had side effects, general weakness, instability, and focal haematoma. Conclusions: Botulinum toxin type A proved a highly useful adjuvant therapy and conservative management in CP.


REFERENCES

  1. Kao I, Drachman DB, Price DL. Botulinum toxin: mechanism of presynaptic blockade. Science 1976;193: 1256-8.

  2. Simpson LL. Kinetic studios on the interaction between botulinum toxic type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980;212:16-21.

  3. Spencer RF, McNeer KW. Botulinum toxin paralysis of adult monkey extraocular muscle. Structural alteration in orbital singly innervated muscle fibers. Arch Ophthalmol 1987;105:1703-11.

  4. American Academy of Ophtalmology Statement: botulinum toxin therapy of eye muscle disorders. Safety and effectiveness. Ophthalmology 1989;11:37-41

  5. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980;87:1044-9.

  6. Denislic M, Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995;26:249-52.

  7. Jankovic J, Schwartz PA. Botulinum toxin injections for cervical dystonias. Neurology 1990;40:277-80.

  8. Rice PG. Pharmacotherapy of spasticity: some theoretical and practical considerations. Can J Neurol Sci 1987;14:510-2.

  9. Burke D. Dorsal rhizotomy for cerebral palsy. Muscle Nerve 1995;18:126.

  10. Logigian EL, Madsen JR, Scot RM. Dorsal rhizotomy for cerebral palsy (a reply). Muscle Nerve 1995;18:127.

  11. Wood KE. The use of phenol as a neurolytic agent; a review. Pain 1978;5:205-29.

  12. Pélissier J, Viel E, Enjalbert M, Kotzki N, Eledjam JJ. Chemical neurolysis using alcohol (alcoholization) in the treatment of spasticity in the hemiplegics. Can Anesthesiol 1993;41(2):139-143.

  13. Biglan AW, Burnstine RA, Rogers GL, Saunders RA. Management of strabismus with botulinum toxin A. Ophthalmology 1989;96:935-43.

  14. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973;12:924-7.

  15. National Institutes of Health Consensus Development. Conference Statement: Clinical use of Botulinum Toxin. Arch Neurol 1991;48:1294-8.

  16. Jankovic J, Orman J. Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987;37:616-23.

  17. Jankovic J, Schwartz K, Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990;53:633-9.

  18. Jankovic J, Schwartz K. Botulin toxin treatment of tremors. Neurology 1991;41(8):1185-8.

  19. Das TK, Park DM. Effect of treatment with botulinum toxin on spasticity. Postgrad Med J 1989;65:208-10.

  20. Consgrove AP. Botulinum toxin in the management of cerebral palsy. Eur J Neurol 1995;2(Suppl 3):73-80.

  21. Hesse S, Lü D, Malexic M, et al. Botulinum toxin: treatment for lower, limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-4.

  22. Dune JW, Heye N, Dunne SL. Treatment for chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232-5.

  23. Bhakta BB, Cozen JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patient with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5.

  24. Chutorian A, Root L, BTA Study Group. A multicenter, randomized, double-blind, placebo controlled trial of botulinum toxin type A (BTA) in the treatment of lower limb spasticity in pediatric cerebral palsy. Mov Disord 1995;10:364.

  25. Simpson DM, Alexander SN, O’Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity. A randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10.

  26. Koman LA, Mooney JF, Smith BP, Goodman A, Mulvaney T. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double blind trial. J Pediatr Orthop 1994;14(3):299-303.

  27. Koman LA, Mooney JF, Smith BP. Management of cerebral palsy with botulinum toxin: a randomized double-blind study (Abstract). Dev Med Child Neurol 1992;34 (Suppl 66):23.

  28. Ashworth, B. Preliminary study of carisoprodol in multiple sclerosis. Practitioner 1964;192:540-542.

  29. Aguilar RF. Uso clínico de la toxina botulínica en enfermedades neurológicas del niño y del adulto. En: Avances de la restauración del sistema nervioso. Ed. Vicova; México, D.F. 1994. p. 459-88.

  30. Allison SC, Abrahan LD, Petersen CL. Reliability of the modified Ashworh scale in the assessment of plantar flexor muscle spasticity in patients with traumatic brain injury. Int J Rehabil Res 1996;19:67-78.

  31. Sindou M, Millet MF. Quantification of spasticity and limb function (based on clinical examination, and directed to adult patients). In: Sindou M, Abbot R, Kerabel Y, eds. Neurosurgery for spasticity. A multidisciplinary approach. Wien:Springer;1991. p. 39-46.

  32. O´Brien C. Management of spasticity associated with stroke. In: O´Brien C, Yablon S, eds. Management of spasticity with botulinum toxin. Litteton, Colorado: Postgraduate Institute of Medicine;1995.p.7-15.

  33. Pullman SL, Greene P, Fahn S, Pedersen SF. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients. Arch Neurol 1996;53:617-24.

  34. Heinen F, Wissel J, Philipsen A, Mall V, Leititis JU, et al. Interventional Neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 1997;28:307-3.

  35. Siatkowske RM, Tyutyunikov A, Biglan AW, Scalise D, Genovese C, Raikow RB, Kennerdell JS, Feuer WJ. Serum antibody production to botulinum A toxin. Ophthalmology 1993;100:1861-6.

  36. Shaari CM, Sanders Y. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis. Muscle Nerve 1993;16:964-9.




2020     |     www.medigraphic.com